THE Health Department has released the minutes of a meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) considering a draft report for the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis.
The review was recommended by the PBAC in late 2015, with the draft report canvassing a range of options addressing cost-effectiveness and proposed changes of eligibility criteria.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 18
